All endpoints met for novel ??-adrenoceptor agonist ATR-258 treating root cause of T2D All endpoints met for novel ??-adrenoceptor agonist ATR-258 treating root cause of T2D
Atrogi Announces Positive Clinical Data from First-in-Class Insulin-Independent Treatment for Type 2 Diabetes
